SG11201808915YA - Chagas antigens and antibodies and compositions, methods and uses thereof - Google Patents

Chagas antigens and antibodies and compositions, methods and uses thereof

Info

Publication number
SG11201808915YA
SG11201808915YA SG11201808915YA SG11201808915YA SG11201808915YA SG 11201808915Y A SG11201808915Y A SG 11201808915YA SG 11201808915Y A SG11201808915Y A SG 11201808915YA SG 11201808915Y A SG11201808915Y A SG 11201808915YA SG 11201808915Y A SG11201808915Y A SG 11201808915YA
Authority
SG
Singapore
Prior art keywords
international
london
rule
ec4a
limited
Prior art date
Application number
SG11201808915YA
Inventor
Mateo Olga Pleguezuelos
Wilson Caparros-Wanderley
Gregory Stoloff
Original Assignee
Peptcell Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Peptcell Ltd filed Critical Peptcell Ltd
Publication of SG11201808915YA publication Critical patent/SG11201808915YA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/002Protozoa antigens
    • A61K39/005Trypanosoma antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55566Emulsions, e.g. Freund's adjuvant, MF59
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) REVISED VERSION --, (19) World Intellectual Property Organization 1111111011111111101 111111111101011101110101H111111111111111111111111110111111111111 International Bureau (10) International Publication Number l i (43) International Publication Date ...../ WO 2017/178660 A9 19 October 2017 (19.10.2017) WIPO I PCT (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, A61K 39/005 (2006.01) C07K 14/44 (2006.01) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, (21) International Application Number: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, PCT/EP2017/059189 HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, (22) International Filing Date: MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, 18 April 2017 (18.04.2017) PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, (25) Filing Language: English TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, 62/322,770 14 April 2016 (14.04.2016) US GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, (71) Applicant: PEPTCELL LIMITED [GB/GB]; 100 Fetter UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, Lane, London Greater London EC4A 1BN (GB). EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, (72) Inventors: PLEGUEZUELOS MATEO, Olga; c/o PepT- MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, cell Limited, 100 Fetter Lane, London Greater London TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, EC4A 1BN (GB). CAPARROS-WANDERLEY, Wilson, KM, ML, MR, NE, SN, TD, TG). Romero; c/o PepTcell Limited, 100 Fetter Lane, London Greater London EC4A 1BN (GB). STOLOFF, Grego- Declarations under Rule 4.17: ry, Alan; c/o PepTcell Limited, 100 Fetter Lane, London — as to applicant's entitlement to apply for and be granted a Greater London EC4A 1BN (GB). patent (Rule 4.1700) (74) Agent: SCHLICH; 9 St. Catherine's Road, Littlehampton West Sussex BN17 5HS (GB). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, (54) Title: CHAGAS ANTIGENS AND ANTIBODIES 100 80 60 Tv 3 40 • A AND COMPOSITIONS, METHODS AND USES THEREOF -a- A+C (control) -0- B D 20 01 0 5 10 15 20 25 30 35 40 45 50 0 Day (pi) IN pc Fig. 12 ,-, N (57) : The present specification discloses Trypanosoma antigens, immunogenic compositions and medicaments comprising 1-1 C such Trypanosoma antigens, methods and uses for such Trypanosoma antigensand immunogenic compositions for treating a Trypano so- ei ma-based disease. C [Continued on next page] WO 2017/178660 A9 IMEDIMOM0101011MOIDEMOMOINIDER011001101MEMHO# Published: — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) — with sequence listing part of description (Rule 5.2(a)) (88) Date of publication of the revised international search report: 07 December 2017 (07.12.2017) (15) Information about Correction: see Notice of 07 December 2017 (07.12.2017)
SG11201808915YA 2016-04-14 2017-04-18 Chagas antigens and antibodies and compositions, methods and uses thereof SG11201808915YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662322770P 2016-04-14 2016-04-14
PCT/EP2017/059189 WO2017178660A1 (en) 2016-04-14 2017-04-18 Chagas antigens and antibodies and compositions, methods and uses thereof

Publications (1)

Publication Number Publication Date
SG11201808915YA true SG11201808915YA (en) 2018-11-29

Family

ID=58671580

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201808915YA SG11201808915YA (en) 2016-04-14 2017-04-18 Chagas antigens and antibodies and compositions, methods and uses thereof

Country Status (18)

Country Link
US (2) US10973897B2 (en)
EP (1) EP3442569A1 (en)
JP (1) JP2019513797A (en)
KR (1) KR20190039022A (en)
CN (2) CN109310747B (en)
AU (1) AU2017248680A1 (en)
BR (1) BR112018071108A2 (en)
CA (1) CA3020856A1 (en)
CL (2) CL2018002932A1 (en)
CO (1) CO2018012295A2 (en)
CU (1) CU20180127A7 (en)
EC (1) ECSP18079073A (en)
MX (1) MX2018012504A (en)
NI (1) NI201800105A (en)
PE (1) PE20190104A1 (en)
RU (1) RU2018139865A (en)
SG (1) SG11201808915YA (en)
WO (1) WO2017178660A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220088161A1 (en) * 2019-01-07 2022-03-24 Genome Research Limited Novel trypanosomal vaccine

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2731370A1 (en) * 1977-07-12 1979-01-25 Behringwerke Ag CHAGA'S VACCINE AND METHOD OF MANUFACTURING IT
ES2169995B1 (en) 2000-04-17 2003-12-01 Leti Lab LIP2A PROTEIN BASED COMPOSITION AND ITS USE IN THE PREPARATION OF A MEDICINAL PRODUCT TO PROVIDE AN IMMUNE RESPONSE AGAINST AN ANTIGEN.
US20040057958A1 (en) 2002-05-17 2004-03-25 Waggoner David W. Immunogenicity-enhancing carriers and compositions thereof and methods of using the same
SA110310855B1 (en) * 2009-11-13 2014-09-16 Laboratories Leti S L Unipersonal The Use of an l3 and/or l5 Source as a Vaccine or as a Diagnostic for a Parasitic Disease
US9804158B2 (en) 2013-07-02 2017-10-31 Institut De Recherche Pour Le Développement Peptides and methods for the detection of Leishmaniasis
US9566320B2 (en) 2013-09-24 2017-02-14 The Board Of Regents Of The University Of Texas System Mucin-associated surface protein as vaccine against Chagas disease

Also Published As

Publication number Publication date
CA3020856A1 (en) 2017-10-19
BR112018071108A2 (en) 2019-02-26
CN109310747A (en) 2019-02-05
CN116059330A (en) 2023-05-05
ECSP18079073A (en) 2019-02-28
CO2018012295A2 (en) 2019-04-30
MX2018012504A (en) 2019-08-29
CL2018002932A1 (en) 2019-02-01
US20170296637A1 (en) 2017-10-19
US20210220453A1 (en) 2021-07-22
NI201800105A (en) 2019-02-18
CN109310747B (en) 2022-11-22
RU2018139865A (en) 2020-05-14
WO2017178660A1 (en) 2017-10-19
PE20190104A1 (en) 2019-01-15
JP2019513797A (en) 2019-05-30
CL2021001441A1 (en) 2021-11-19
KR20190039022A (en) 2019-04-10
US10973897B2 (en) 2021-04-13
CU20180127A7 (en) 2019-08-06
WO2017178660A9 (en) 2017-12-07
AU2017248680A1 (en) 2018-11-22
EP3442569A1 (en) 2019-02-20

Similar Documents

Publication Publication Date Title
SG11201903514VA (en) Novel cd47 monoclonal antibodies and uses thereof
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201903882VA (en) Il-2 variants for the treatment of autoimmune diseases
SG11201805320XA (en) Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration
SG11201906200WA (en) Nucleic acid-polypeptide compositions and methods of inducing exon skipping
SG11201810600WA (en) Fxr (nr1h4) modulating compounds
SG11201907889YA (en) Glycan-interacting compounds and methods of use
SG11201906192SA (en) Methods of treating cancer with anti-pd-1 antibodies
SG11201810023QA (en) Anti-tim-3 antibodies and methods of use thereof
SG11201901020RA (en) Anti-siglec-7 antibodies for the treatment of cancer
SG11201909949XA (en) Targeted immunotolerance
SG11201809700YA (en) Gdf15 fusion proteins and uses thereof
SG11201810465RA (en) Compositions and methods related to engineered fc constructs
SG11201804814YA (en) Materials and methods for delivering nucleic acids to cochlear and vestibular cells
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201804375WA (en) Compositions and methods for internalizing enzymes
SG11201806496SA (en) Antigen binding proteins that bind pd-l1
SG11201408095XA (en) Fibroblast growth factor 21 proteins
SG11201908326YA (en) Methods of treating neurodegenerative diseases
SG11201810280YA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201908512YA (en) Somatostatin modulators and uses thereof
SG11201900554YA (en) Spiro-lactam nmda modulators and methods of using same
SG11201809374VA (en) Cd40l-fc fusion polypeptides and methods of use thereof
SG11201806342SA (en) Glucagon and glp-1 co-agonists for the treatment of obesity
SG11201810525XA (en) Anti-gitr antibodies and uses thereof